USPTO serial 79374502
AFFIBODY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 27, 2025
- Examiner
- SWIFT, GILBERT M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AFFIBODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica S. Sachs
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.5445 Corporate DriveSuite 200Troy, MI 48098Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical substances and materials for industrial, scientific and laboratory use other than for medical or veterinary purposes; chemical reagents other than for medical or veterinary purposes, biochemical preparations for scientific purposes; biochemical substances for scientific purposes; chemical substances for use in the production of drugs, pharmaceuticals and antibodies; reagents for scientific, laboratory, analysis, research, medical research, testing, inspection, detecting or verification use other than for medical or veterinary purposes; reagents for use in the development of antibodies other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis other than for medical or veterinary purposes; antibodies and antibodies-based chemicals, except for medical or veterinary use | ACTIVE | — |
| 005 | Medical and veterinary substances, preparations and articles, namely, Medical diagnostic reagents and assays for testing of bodily fluids, Clinical diagnostic reagents for medical use, Diagnostic biomarker reagents for medical purposes, Diagnostic reagents and agents for medical diagnostic use, Diagnostic reagents for clinical laboratory use, Reagents for use in medical genetic testing, Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, contrast media for use with imaging medical equipment; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of neoplasms, cancer diseases, inflammatory eye, skin, muscle and joint diseases and disorders, diseases and disorders of the immune system, autoimmune diseases and disorders, local and systemic bacterial infections, viral infections, fungal infections, central nervous system (CNS) diseases, circulatory system, respiratory system, respiratory diseases and disorders, cardiovascular diseases, renal diseases, liver diseases, skin diseases, diseases of the digestive system, gastro-intestinal diseases, eye diseases and conditions, diseases of the musculoskeletal system or connective tissue; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies, diseases of the blood or blood forming organs; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of disorders of the lymphatic systems namely Lymphangitis, Lymphocytosis, and Mesenteric lymphadenitis; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of metabolic diseases namely obesity, diabetes, metabolic syndrome, inborn errors of metabolism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the endocrine system, namely glucose homeostasis disorders, thyroid disorders, calcium homeostasis disorders and metabolic bone disease, pituitary gland disorders, sex hormone disorders and tumours of the endocrine glands; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the genitourinary system, namely prostate, reproductive and urological diseases and disorders; diagnostic preparations and materials for medical purposes; medical therapeutic agents for regulation of biological functions, protein inhibition or activation, weight control and appetite suppression; reagents for medical, surgical, veterinary and dental use; biochemical biomarkers for medical use; diagnostic biomarker reagents for medical purposes; sanitary preparations for medical purposes | ACTIVE | — |
| 010 | Medical and veterinary apparatus and instruments, namely, medical apparatus and instruments for use in surgery, chromatography media in the nature of liquid chromatography apparatus for medical use in medical research; diagnostic, examination, and monitoring equipment namely, medical apparatus and instruments for diagnostic radiopharmaceutical use; screening apparatus and instruments for medical purposes, namely, ultrasonic medical diagnostic apparatus; separation instruments for medical use, namely, tubing and valve assembly set and electromechanical fluidic instrument, and other similar or related devices, which process human whole blood for the purpose of separating human blood components for use in blood transfusions and washing human red blood cells with clinical medical reagents for use in blood transfusions chromatography columns for use in affinity separation, chromatography media for use in affinity separation; gas chromatographic instruments for medical use; diagnostic imaging apparatus for medical use; medication fluid injectors | ACTIVE | — |
| 042 | Scientific research, technological research, product development and design in the field of biotechnics and diagnostics; medical and pharmacological research services for medical purposes in the field of biotechnics and diagnostics; medical, pharmaceutical and biotechnological laboratory research services for medical purposes in the field of biotechnics and diagnostics; scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials for others; providing scientific information about the results of clinical trials for pharmaceutical products; scientific advisory services relating to diagnostic preparations; biochemical analysis and research for medical purposes in the field of biotechnics and diagnostics; drug discovery services; pharmaceutical products development and evaluation | ACTIVE | — |
| 044 | Human healthcare services; medical services; providing medical information; physical examination; medical diagnostic testing, monitoring and reporting services; optical medical imaging for medical diagnostic use; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing for diagnostic or treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Affibody AB
- Other trademarks owned by Affibody AB
- Other trademarks owned by Affibody AB
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AFFIBODY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 8, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 22, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 22, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 27, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 27, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 27, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 8, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 8, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 2, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 13, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 13, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 13, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 13, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 5, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 4, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 18, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 18, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 16, 2024 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Sep 16, 2024 | GNSF | SUBSEQUENT FINAL EMAILED | — |
| Sep 16, 2024 | CFRC | SUBSEQUENT FINAL REFUSAL WRITTEN | — |
| Sep 11, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 11, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 11, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 9, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 31, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 11, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 11, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 29, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 25, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 21, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 20, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |